EP3241551A4 - Pharmazeutische zusammensetzung zur krebsbehandlung mit laktatmetallsalz - Google Patents

Pharmazeutische zusammensetzung zur krebsbehandlung mit laktatmetallsalz Download PDF

Info

Publication number
EP3241551A4
EP3241551A4 EP15875540.5A EP15875540A EP3241551A4 EP 3241551 A4 EP3241551 A4 EP 3241551A4 EP 15875540 A EP15875540 A EP 15875540A EP 3241551 A4 EP3241551 A4 EP 3241551A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
metal salt
treating cancer
containing lactate
lactate metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15875540.5A
Other languages
English (en)
French (fr)
Other versions
EP3241551A1 (de
EP3241551B1 (de
Inventor
Hwan Mook Kim
Keun Yeong Jeong
Jae Jun Sim
Yeong Su Jang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metimedi Pharmaceuticals Co Ltd
Original Assignee
Metimedi Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metimedi Pharmaceuticals Co Ltd filed Critical Metimedi Pharmaceuticals Co Ltd
Priority to SI201531417T priority Critical patent/SI3241551T1/sl
Priority to RS20201338A priority patent/RS61086B1/sr
Priority to PL15875540T priority patent/PL3241551T3/pl
Publication of EP3241551A1 publication Critical patent/EP3241551A1/de
Publication of EP3241551A4 publication Critical patent/EP3241551A4/de
Application granted granted Critical
Publication of EP3241551B1 publication Critical patent/EP3241551B1/de
Priority to HRP20201819TT priority patent/HRP20201819T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP15875540.5A 2014-12-29 2015-12-04 Pharmazeutische zusammensetzung zur krebsbehandlung mit laktatmetallsalz Active EP3241551B1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SI201531417T SI3241551T1 (sl) 2014-12-29 2015-12-04 Farmacevtska sestava za zdravljenje raka, ki vsebuje laktat kovinsko sol
RS20201338A RS61086B1 (sr) 2014-12-29 2015-12-04 Farmaceutska kompozicija za tretiranje kancera koja sadrži metalnu so laktata
PL15875540T PL3241551T3 (pl) 2014-12-29 2015-12-04 Kompozycja farmaceutyczna do leczenia nowotworu zawierająca sól mleczanową metalu
HRP20201819TT HRP20201819T1 (hr) 2014-12-29 2020-11-16 Farmaceutski pripravak za liječenje raka koji sadrži laktatnu metalnu sol

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20140192158 2014-12-29
KR1020150142828A KR101683635B1 (ko) 2014-12-29 2015-10-13 락테이트 금속염을 포함하는 암 치료용 약학 조성물
PCT/KR2015/013191 WO2016108446A1 (ko) 2014-12-29 2015-12-04 락테이트 금속염을 포함하는 암 치료용 약학 조성물

Publications (3)

Publication Number Publication Date
EP3241551A1 EP3241551A1 (de) 2017-11-08
EP3241551A4 true EP3241551A4 (de) 2018-07-11
EP3241551B1 EP3241551B1 (de) 2020-09-16

Family

ID=56499541

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15875540.5A Active EP3241551B1 (de) 2014-12-29 2015-12-04 Pharmazeutische zusammensetzung zur krebsbehandlung mit laktatmetallsalz

Country Status (31)

Country Link
US (2) US10525022B2 (de)
EP (1) EP3241551B1 (de)
JP (2) JP7103789B2 (de)
KR (3) KR101683635B1 (de)
CN (1) CN107405320B (de)
AU (1) AU2015372945B2 (de)
BR (1) BR112017013829A2 (de)
CA (1) CA2972610C (de)
CL (1) CL2017001721A1 (de)
CO (1) CO2017007425A2 (de)
CY (1) CY1123726T1 (de)
DK (1) DK3241551T3 (de)
EA (1) EA037279B1 (de)
ES (1) ES2833016T3 (de)
HK (1) HK1245084A1 (de)
HR (1) HRP20201819T1 (de)
HU (1) HUE052576T2 (de)
IL (1) IL253048B2 (de)
LT (1) LT3241551T (de)
MX (1) MX2017008641A (de)
MY (1) MY190972A (de)
NZ (1) NZ734162A (de)
PH (1) PH12017501221A1 (de)
PL (1) PL3241551T3 (de)
PT (1) PT3241551T (de)
RS (1) RS61086B1 (de)
SG (2) SG11201705357PA (de)
SI (1) SI3241551T1 (de)
UA (1) UA122218C2 (de)
WO (1) WO2016108446A1 (de)
ZA (1) ZA201705148B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
KR102431011B1 (ko) * 2016-10-05 2022-08-09 고쿠리츠다이가쿠호진 도호쿠다이가쿠 림프행성 약제 투여법으로 유효한 약제
KR20180062063A (ko) 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
CN117130035A (zh) * 2017-08-18 2023-11-28 南京中硼联康医疗科技有限公司 生物剂量计及具有其的中子捕获治疗系统
EP3737363A4 (de) 2018-01-12 2021-10-20 Metimedi Pharmaceuticals Co., Ltd Verfahren zur behandlung chronisch entzündlicher erkrankungen
KR101998246B1 (ko) * 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
WO2024010394A1 (ko) * 2022-07-07 2024-01-11 (주) 메티메디제약 칼슘 락테이트를 유효성분으로 함유하는 암성 악액질 개선 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064178A1 (en) * 2010-09-13 2012-03-15 Carolyn Flora Anne Dean Cell-8 Solution
CN103110133A (zh) * 2012-11-15 2013-05-22 沈阳洪达信息科技有限公司 一种含有阿胶的火腿肠
CN103535580A (zh) * 2013-10-22 2014-01-29 武汉哈福科技有限公司 一种补充多种微量元素的保健食品及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
CN1104625A (zh) * 1994-03-21 1995-07-05 张景春 乳酸铬、铜、锰及制备工艺和用途
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6036985A (en) 1998-04-03 2000-03-14 Nestec S.A. Calcium complex and food fortified therewith
US5980863A (en) 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
US6251439B1 (en) * 1998-12-16 2001-06-26 Trustee Of The Dartmouth College Composition and method for reducing the risk of carcinogenesis
WO2000067750A1 (en) 1999-05-05 2000-11-16 Unilever N.V. Food product
US6261610B1 (en) 1999-09-24 2001-07-17 Nestec S.A. Calcium-magnesium fortified water, juices, beverages and other liquid food products and process of making
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
EP1129715A1 (de) 2000-02-25 2001-09-05 Werner Dr. Reichen Anwendung von Magnesium, Kalzium und Silizium zur Heilung verschiedener Krankheiten und zum allgemeinen Wohlbefinden
US6687428B2 (en) 2000-09-21 2004-02-03 Tera Op (Usa) Inc. Optical switch
US20040071789A1 (en) 2002-02-14 2004-04-15 Baron John A Calcium supplementation to reduce prostate cancer risk
NZ527609A (en) 2001-02-16 2004-04-30 Dartmouth College Elemental calcium to reduce prostate cancer risk
JP2004530659A (ja) 2001-02-28 2004-10-07 ジャイルズ，ブライアン，シー． 抗腫瘍および抗転移作用のための方法および処方
ITMI20011495A1 (it) 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
FR2834641B1 (fr) 2002-01-14 2005-04-22 Ct Regional De Lutte Contre Le Protection de la neurotoxicite de l'oxaliplatine par administration de calcium et de magnesium
HUP0200337A2 (hu) 2002-01-30 2005-09-28 Sanofi-Aventis Stabilizált provastatin-nátriumot tartalmazó gyógyászati készítmény
DE10233229A1 (de) 2002-07-22 2004-02-12 S.K. Enterprise Gmbh Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels
US20040253323A1 (en) 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
WO2005077405A1 (en) 2004-02-06 2005-08-25 Cancer Treatment International Compositions and methods for the treatment of cancer by systemic elevation of lactate and consequent depletion of arginine
ITMI20041822A1 (it) 2004-09-24 2004-12-24 Pharmaproducts Uk Ltd "agente terapeutico utile per il trattamento di neoplasie plasmacellulari"
IL166114A0 (en) 2005-01-03 2006-01-15 Calcident Active Ltd Long-acting controlled-release pharmaceutical preparation for use in the oral cavity
UA95093C2 (uk) 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
US20070292493A1 (en) 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
WO2008005509A2 (en) 2006-07-06 2008-01-10 Massachusetts Institute Of Technology Methods and compositions for altering biological surfaces
EP2123258A1 (de) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomen zur Arzneimittelverabreichung
US8871458B2 (en) 2008-12-29 2014-10-28 Wake Forest University Health Sciences Methods for detecting risk of fatal prostate cancer using serum calcium
CA2754684A1 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
US20110117210A1 (en) * 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
WO2011152810A1 (en) 2010-06-03 2011-12-08 Bilgic Mahmut Formulations comprising calcium, vitamin d and vitamin k for osteoporosis
CN102085217B (zh) * 2011-01-06 2012-02-15 上海交通大学医学院附属仁济医院 含有药用钙盐的早期预防大肠腺瘤或者大肠癌的药物组合物
EP2599477A1 (de) 2011-11-30 2013-06-05 Lunamed AG Verzögerte Freisetzungsformulierung mit 4-Phenylbuttersäure
EP2785357A4 (de) 2011-12-04 2015-08-26 David L Liu Pharmazeutische zusammensetzungen aus natriumion und calciumion und verfahren zur behandlung von krebs, tumoren und gutartigen erscheinungen
US9943599B2 (en) 2011-12-22 2018-04-17 Herlev Hospital Therapeutic applications of calcium electroporation to effectively induce tumor necrosis
UA103694C2 (en) 2012-02-20 2013-11-11 Евгений Иванович Суслов Antitumor drug
US20150366908A1 (en) 2012-06-07 2015-12-24 Novabone Products, Llc Silica-coated calcium salt compositions
WO2013184943A1 (en) 2012-06-07 2013-12-12 Novabone Products, Llc Silica-coated calcium salt compositions
US10675246B2 (en) * 2013-03-15 2020-06-09 Cerolife Llc Orally administrable compositions comprising calcium
EP2799060A1 (de) * 2013-04-30 2014-11-05 Aprofol AG Stabile hochdosierte pharmazeutische Zusammensetzung enthaltend Levoleucovorin
CN105311051A (zh) 2014-05-26 2016-02-10 陈松源 具有增加抗肿瘤药物疗效的载体溶媒、制备方法及其给药途径
JP6736004B2 (ja) 2014-12-24 2020-08-05 国立大学法人東海国立大学機構 抗癌剤および輸液とそれらの製造方法ならびに抗癌物質
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064178A1 (en) * 2010-09-13 2012-03-15 Carolyn Flora Anne Dean Cell-8 Solution
CN103110133A (zh) * 2012-11-15 2013-05-22 沈阳洪达信息科技有限公司 一种含有阿胶的火腿肠
CN103535580A (zh) * 2013-10-22 2014-01-29 武汉哈福科技有限公司 一种补充多种微量元素的保健食品及其制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JANG YEONG-SU ET AL: "Investigation of lactate calcium salt-induced beta-catenin destabilization in colorectal cancer cells", LIFE SCIENCES, vol. 139, October 2015 (2015-10-01), pages 160 - 165, XP029287314 *
STEVENS C D ET AL: "INHIBITION OF AN EHRLICH ASCITES TUMOR IN VIVO BY PARTIALLY NEUTRALIZED SOLUTIONS OF SODIUM LACTATE.", BRITISH JOURNAL OF CANCER JUN 1963, vol. 17, June 1963 (1963-06-01), pages 315 - 319, XP002781194, ISSN: 0007-0920 *
SUNDARAMOORTHY PASUPATHI ET AL: "Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain", PLOS ONE, vol. 10, no. 1, January 2015 (2015-01-01), XP002781193 *
WARGOVICH M J ET AL: "Inhibition of the promotional phase of azoxymethane-induced colon carcinogenesis in the F344 rat by calcium lactate: effect of simulating two human nutrient density levels", CANCER LETTERS, NEW YORK, NY, US, vol. 53, no. 1, 1 August 1990 (1990-08-01), pages 17 - 25, XP023162625, ISSN: 0304-3835, [retrieved on 19900801], DOI: 10.1016/0304-3835(90)90005-I *

Also Published As

Publication number Publication date
JP2018502913A (ja) 2018-02-01
HK1245084A1 (zh) 2018-08-24
CO2017007425A2 (es) 2017-10-20
AU2015372945B2 (en) 2020-12-24
UA122218C2 (uk) 2020-10-12
NZ734162A (en) 2024-07-05
MX2017008641A (es) 2018-04-26
IL253048B1 (en) 2023-04-01
PH12017501221A1 (en) 2018-01-08
HUE052576T2 (hu) 2021-05-28
LT3241551T (lt) 2021-01-25
DK3241551T3 (da) 2020-11-09
BR112017013829A2 (pt) 2018-02-27
RS61086B1 (sr) 2020-12-31
SI3241551T1 (sl) 2021-01-29
CA2972610C (en) 2023-04-04
JP2021020916A (ja) 2021-02-18
EA201791384A1 (ru) 2017-12-29
US11413261B2 (en) 2022-08-16
AU2015372945A1 (en) 2017-08-10
KR20170029482A (ko) 2017-03-15
KR20160082918A (ko) 2016-07-11
IL253048A0 (en) 2017-08-31
KR101749308B1 (ko) 2017-06-21
PL3241551T3 (pl) 2021-04-19
US10525022B2 (en) 2020-01-07
ES2833016T3 (es) 2021-06-14
CN107405320B (zh) 2023-06-20
ZA201705148B (en) 2021-01-27
SG11201705357PA (en) 2017-10-30
EP3241551A1 (de) 2017-11-08
US20170360727A1 (en) 2017-12-21
WO2016108446A1 (ko) 2016-07-07
US20200113855A1 (en) 2020-04-16
HRP20201819T1 (hr) 2021-04-16
CL2017001721A1 (es) 2018-03-16
IL253048B2 (en) 2023-08-01
CA2972610A1 (en) 2016-07-07
JP7103789B2 (ja) 2022-07-20
EP3241551B1 (de) 2020-09-16
PT3241551T (pt) 2020-11-24
KR101683635B1 (ko) 2016-12-09
SG10201906073UA (en) 2019-08-27
CY1123726T1 (el) 2022-03-24
CN107405320A (zh) 2017-11-28
KR20160128284A (ko) 2016-11-07
EA037279B1 (ru) 2021-03-03
MY190972A (en) 2022-05-25
KR101880542B1 (ko) 2018-07-20

Similar Documents

Publication Publication Date Title
EP3288382A4 (de) Verfahren zur behandlung von krebs
EP3552611A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von krebs mit kristallinem tetraarsen-hexoxid-polymorph
EP3092254A4 (de) Verbindungen und zusammensetzungen zur behandlung von her2-positiven tumoren
EP3263132A4 (de) Zusammensetzung zur behandlung von il-6-assoziierten erkrankungen
SI3377516T1 (sl) Sestavek za zdravljenje raka
IL249231A0 (en) Pharmaceutical combinations for cancer treatment
HK1245084A1 (zh) 用於治療癌症的包含金屬乳酸鹽的藥物組合物
EP3111761A4 (de) Agrochemische zusammensetzung zur blattwerkbehandlung
EP3214090A4 (de) Thionucleosidderivat oder salz daraus und pharmazeutische zusammensetzung
EP3389634A4 (de) Verfahren zur behandlung von krebs
EP3139919A4 (de) Verbindungen zur behandlung von krebs
EP3389652A4 (de) Verfahren zur behandlung von krebs
EP3169686A4 (de) Verfahren zur behandlung von krebs mit substituierten pyrrolopyrimidinverbindungen, zusammensetzungen davon
EP3156055A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von muskelschwächebedingten erkrankungen mit butylpyridinium oder derivat davon
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
EP3099297A4 (de) Neuartiges verfahren zur behandlung von krebs
EP3194025A4 (de) Verfahren zur prävention oder behandlung von osteoarthritis
EP3153244A4 (de) Verfahren zur inaktivierung von natriummetall
EP3129378A4 (de) Bromodomainhemmende verbindungen und pharmazeutische zusammensetzung damit zur prävention oder behandlung von krebs
HK1232128A1 (zh) 用於預防或治療皮疹的藥物組合物
EP3148547A4 (de) Verfahren zur behandlung von arzneimittelresistentem krebs
EP3369419A4 (de) Zusammensetzung zur behandlung von diabetes
HUE051563T2 (hu) Gyógyszerkészítmény rák megelõzésére vagy kezelésére
EP3120853A4 (de) Pharmazeutische zusammensetzung zur behandlung von stk11-mutationskrebs mit herzglycosiden
EP3193879A4 (de) Injizierbare formulierungen zur behandlung von krebs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/506 20060101ALI20180530BHEP

Ipc: A61K 9/48 20060101ALI20180530BHEP

Ipc: A23L 33/10 20160101ALI20180530BHEP

Ipc: A61K 9/00 20060101ALI20180530BHEP

Ipc: A61K 45/06 20060101ALI20180530BHEP

Ipc: A61P 35/00 20060101ALI20180530BHEP

Ipc: A61K 9/08 20060101ALI20180530BHEP

Ipc: A61K 31/191 20060101ALI20180530BHEP

Ipc: A61K 9/70 20060101ALI20180530BHEP

Ipc: A61K 31/19 20060101AFI20180530BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180608

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200108

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200422

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015059344

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1313508

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201015

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20201104

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20201819T

Country of ref document: HR

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3241551

Country of ref document: PT

Date of ref document: 20201124

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20201118

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20201819T

Country of ref document: HR

Payment date: 20201202

Year of fee payment: 6

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20200916

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E020012

Country of ref document: EE

Effective date: 20201118

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 35958

Country of ref document: SK

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20201222

Year of fee payment: 6

Ref country code: MC

Payment date: 20201209

Year of fee payment: 6

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20201819

Country of ref document: HR

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E052576

Country of ref document: HU

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20201123

Year of fee payment: 6

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2833016

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210614

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015059344

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20210617

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20201819

Country of ref document: HR

Payment date: 20211202

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20211201

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20211208

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20211201

Year of fee payment: 7

Ref country code: MK

Payment date: 20211202

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20211206

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220707

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20201819

Country of ref document: HR

Payment date: 20221130

Year of fee payment: 8

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20221204

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221204

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221204

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221204

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20201819

Country of ref document: HR

Payment date: 20231128

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231201

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231214

Year of fee payment: 9

Ref country code: GB

Payment date: 20231220

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20231215

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231130

Year of fee payment: 9

Ref country code: SI

Payment date: 20231127

Year of fee payment: 9

Ref country code: SE

Payment date: 20231219

Year of fee payment: 9

Ref country code: RS

Payment date: 20231129

Year of fee payment: 9

Ref country code: RO

Payment date: 20231127

Year of fee payment: 9

Ref country code: PT

Payment date: 20231128

Year of fee payment: 9

Ref country code: NO

Payment date: 20231218

Year of fee payment: 9

Ref country code: NL

Payment date: 20231219

Year of fee payment: 9

Ref country code: LU

Payment date: 20231218

Year of fee payment: 9

Ref country code: IE

Payment date: 20231218

Year of fee payment: 9

Ref country code: HU

Payment date: 20231231

Year of fee payment: 9

Ref country code: HR

Payment date: 20231128

Year of fee payment: 9

Ref country code: FR

Payment date: 20231219

Year of fee payment: 9

Ref country code: FI

Payment date: 20231218

Year of fee payment: 9

Ref country code: EE

Payment date: 20231222

Year of fee payment: 9

Ref country code: DK

Payment date: 20231219

Year of fee payment: 9

Ref country code: CZ

Payment date: 20231127

Year of fee payment: 9

Ref country code: BG

Payment date: 20231220

Year of fee payment: 9

Ref country code: AT

Payment date: 20231214

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231127

Year of fee payment: 9

Ref country code: BE

Payment date: 20231218

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240118

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231229

Year of fee payment: 9

Ref country code: CH

Payment date: 20240110

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231229

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220412